Myungmoon Pharm Co Ltd

Myungmoon Pharm Co Ltd has a debt-to-equity ratio of 1.08, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is weak, with a current ratio of 0.68, suggesting that it may struggle to meet short-term obligations without external financing. The company's cash and equivalents of KRW 3.6 billion are insufficient to cover its long-term debt of KRW 88.9 billion, resulting in a net cash deficit.

The company's profitability metrics are negative, with a return on equity of -1.48% and a return on assets of -0.52%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit. The operating loss of KRW 941 million and net loss of KRW 1.2 billion further underscore the company's financial challenges.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks.

The company's revenue for the latest period was KRW 44.2 billion, but there is no provided outlook for the current or next fiscal year. The operating cash flow of KRW -2.9 billion and free cash flow of KRW -718 million indicate a lack of internal cash generation, which may hinder the company's ability to fund operations or growth initiatives.

The company's risk assessment highlights medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential refinancing challenges. The company has not disclosed any dilutive events in the near term, and the risk of equity dilution remains low.

Recent financial filings show a continued operating loss and negative cash flows, with no material events disclosed in the latest transcripts or filings. The company's financial health appears to be deteriorating, with no clear turnaround strategy outlined in the available data.

Operating income surged 536.1% year-over-year to 6.8 billion KRW, signaling a strong operational turnaround.

Revenue grew 4.7% year-over-year to 195.2 billion KRW, demonstrating consistent top-line expansion.

Cash conversion ratio of 2.38 exceeds the pharmaceutical cohort median of 0.95, indicating superior efficiency.

Capital expenditure relative to revenue is above the 75th percentile, suggesting robust investment in growth.

Net income improved 162.5% year-over-year, turning a previous loss into a 1.9 billion KRW profit.

The company carries a high credit risk flag, indicating significant concerns regarding its debt servicing ability.

Debt-to-equity ratio of 1.08 is in the bottom quartile, far exceeding the cohort median of 0.18.